Figure 8

267/Dt combination therapy in vivo correlates with reduced tumor burden and extended survival in orthotopic LCC6 breast cancer tumor model. Bioluminescent imaging of orthotopic LCC6 tumors are shown one day after treatment initiation and on day 22 after treatment initiation. The treatment groups included (a and e) vehicle controls, (b and f) QLT0267 (267), (c and g) docetaxel (Dt), and the (d and h) combination of 267/Dt treated animals (doses indicated on graph). Total light emission from tumors in animals was visualized and quantified. (i) Animals treated with the combination showed lower total light flux than all other treatment groups. Animals treated with 267 exhibited tumors with darkened areas in the core (see inset in f as an example). Tumor size in treated animals was measured by callipers and these data were used to estimate the (j) tumor volumes. The combination of 267/Dt was significantly lower (***P < 0.005) then all other treatment groups analyzed. (k) Kaplan-Meier survival analysis of data defining survival endpoints based on tumor ulceration and/or tumors more than 0.5 g were used to determine median survival times. For animals treated with 267 (200 mg/kg) the median survival time was 33 days (26 days post-treatment initiation), animals treated with Dt (5 mg/kg) exhibited a median survival time of 31 days (24 days post-treatment initiation); and animals treated with the 267/Dt combination exhibited a median survival time of more than 90 days (83 days post-treatment initiation). In this group three out of five animals were alive at day 90, while no animals were alive for any other treatment group.